Vaccine Info

AV7909 Anthrax Vaccine

Authored by
Last reviewed
February 26, 2022
Fact checked by
Robert Carlson, MD

AV7909 Anthrax Description

AV7909 is a combination of BioThrax (also called anthrax vaccine, adsorbed or AVA), an FDA-licensed vaccine, and CPG 7909.

CPG 7909 is a synthetic short DNA sequence that has been shown to be an effective vaccine adjuvant, which increases the speed and the degree of the immune response to Protective Antigen (PA), the major vaccine antigen.

AV7909 Anthrax Indication

AV7909 is indicated for post-exposure prophylaxis of anthrax disease

AV7909 Anthrax Dosage

AV7909 offers a two-dose schedule that elicits a rapid immune response especially advantageous during an anthrax event

It is given as an intramuscular injection.  The number of injections and dose of vaccine is being evaluated in ongoing clinical trials.

AV7909 Anthrax News

February 24, 2022- Emergent BioSolutions reported financial reports for the fourth quarter and year ended December 31, 2021. Initiated the rolling submission to the U.S. Food and Drug Administration (FDA) of the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted), the Company’s investigational anthrax vaccine candidate.

AV7909 Anthrax Clinical Trial

Clinical Trial NCT03877926: VELOCITY: An Anthrax Vaccine Clinical Study

  • A Phase 3, multicenter, randomized, double-blind, parallel-group trial designed to evaluate the lot consistency (using three consecutively manufactured lots), immunogenicity, and safety of AV7909 administered in healthy adults for an indication of postexposure prophylaxis (PEP) of anthrax
  • AV7909 consists of Anthrax Vaccine Adsorbed (AVA) drug substance and CPG 7909 adjuvant.
  • AVA drug substance is identical in composition and manufacturing process to commercial BioThrax.
  • CPG 7909 is an immunostimulatory synthetic oligodeoxynucleotide that functions as an adjuvant. It is designed to induce an enhanced immune response.

Clinical Trials

No clinical trials found